An update on the clinical consequences of polypharmacy in older adults: a narrative review
Open accessThe DOI matches its Crossref record; 96 of the 96 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Polypharmacy, the use of multiple medications by one individual, is increasingly common among older adults. Caring for the growing number of older people with complex drug regimens and multimorbidity presents an important challenge in the coming years. AREAS COVERED: This article reviews the international trends in the prevalence of polypharmacy, summarizes the results from previous reviews on polypharmacy and negative health outcomes, and updates a previous review on the clinical consequences of polypharmacy by focusing on studies published after 2013. This narrative review, which is based on a literature search in MEDLINE and EMBASE from January 1990 to June 2018, was undertaken to identify relevant articles. Search terms included variations of polypharmacy and multiple medications. EXPERT OPINION: The prevalence of polypharmacy is increasing worldwide. More than half of the older population is exposed to polypharmacy in some settings. Polypharmacy is associated with a broad range of clinical consequences. However, methods to assess the dangers of polypharmacy should be refined. In our opinion, the issue of 'confounding by multimorbidity' has been underestimated and should be better accounted for in future studies. Moreover, researchers should develop more clinically relevant definitions of polypharmacy, including measures of inappropriate or problematic polypharmacy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Chronic BZD use is also a concern for older adults as they are likely to be prescribed multiple medications, increasing their risk of morbidity and mortality from polypharmacy.94,95”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [94]
In the citing paper
“Chronic BZD use is also a significant concern for older adults given they are likely to be prescribed multiple medications, increasing their risk of morbidity and mortality from polypharmacy.94,95”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [94]
Citations
Cites
Barnett, K., Mercer, S. W., Norbury, M., Watt, G., Wyke, S., & Guthrie, B. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60240-2 · Cited by 6,972
Validation of a combined comorbidity index
Charlson, M., Szatrowski, T. P., Peterson, J., & Gold, J. (1994) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)90129-5 · Cited by 6,587
What is polypharmacy? A systematic review of definitions
Masnoon, N., Shakib, S., Kalisch-Ellett, L., & Caughey, G. E. (2017) · BMC Geriatrics · doi:10.1186/s12877-017-0621-2 · Cited by 3,293
By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel (2015) · Journal of the American Geriatrics Society · doi:10.1111/jgs.13702 · Cited by 2,609
Boyd, C. M., Darer, J., Boult, C., Fried, L. P., Boult, L., & Wu, A. W. (2005) · JAMA · doi:10.1001/jama.294.6.716 · Cited by 2,581
STOPP/START criteria for potentially inappropriate prescribing in older people: version 2
O'Mahony, D., O'Sullivan, D., Byrne, S., O'Connor, M. N., Ryan, C., & Gallagher, P. (2014) · Age and Ageing · doi:10.1093/ageing/afu145 · Cited by 2,397
Clinical consequences of polypharmacy in elderly
Maher, R. L., Hanlon, J., & Hajjar, E. R. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.827660 · Cited by 1,938
Reducing Inappropriate Polypharmacy: The Process of Deprescribing
Scott, I. A., Hilmer, S. N., Reeve, E., Potter, K., Le Couteur, D., Rigby, D., Gnjidic, D., Del Mar, C. B., Roughead, E. E., Page, A., et al. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.0324 · Cited by 1,584
Trends in Prescription Drug Use Among Adults in the United States From 1999-2012
Kantor, E. D., Rehm, C. D., Haas, J. S., Chan, A. T., & Giovannucci, E. L. (2015) · JAMA · doi:10.1001/jama.2015.13766 · Cited by 1,219
Gnjidic, D., Hilmer, S. N., Blyth, F. M., Naganathan, V., Waite, L., Seibel, M. J., McLachlan, A. J., Cumming, R. G., Handelsman, D. J., & Le Couteur, D. G. (2012) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2012.02.018 · Cited by 1,176
The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995–2010
Guthrie, B., Makubate, B., Hernandez-Santiago, V., & Dreischulte, T. (2015) · BMC Medicine · doi:10.1186/s12916-015-0322-7 · Cited by 838
Interventions to improve the appropriate use of polypharmacy for older people
Patterson, S. M., Cadogan, C. A., Kerse, N., Cardwell, C. R., Bradley, M. C., Ryan, C., & Hughes, C. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008165.pub3 · Cited by 754
Managing patients with multimorbidity in primary care
Wallace, E., Salisbury, C., Guthrie, B., Lewis, C., Fahey, T., & Smith, S. M. (2015) · BMJ · doi:10.1136/bmj.h176 · Cited by 742
Health Outcomes Associated with Polypharmacy in Community‐Dwelling Older Adults: A Systematic Review
Fried, T. R., O'Leary, J., Towle, V., Goldstein, M. K., Trentalange, M., & Martin, D. K. (2014) · Journal of the American Geriatrics Society · doi:10.1111/jgs.13153 · Cited by 721
Qato, D. M., Wilder, J., Schumm, L. P., Gillet, V., & Alexander, G. C. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.8581 · Cited by 658
Polypharmacy Among Adults Aged 65 Years and Older in the United States: 1988–2010
Charlesworth, C. J., Smit, E., Lee, D. S. H., Alramadhan, F., & Odden, M. C. (2015) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glv013 · Cited by 570 · cited 1×
“Some specific drug classes that have been linked to the increase in polypharmacy include, among others, cardiovascular drugs (especially statins), antidepressants, and proton pump inhibitors [19,20].”
BackgroundConfounding by Indication in Clinical Research
Kyriacou, D. N., & Lewis, R. J. (2016) · JAMA · doi:10.1001/jama.2016.16435 · Cited by 565 · cited 1×
“Confounding by indication is a well-described bias in the medical literature [83].”
BackgroundPolypharmacy in the elderly: A literature review
Fulton, M. M., & Riley Allen, E. (2005) · Journal of the American Academy of Nurse Practitioners · doi:10.1111/j.1041-2972.2005.0020.x · Cited by 540
Interventions to improve the appropriate use of polypharmacy for older people
Rankin, A., Cadogan, C. A., Patterson, S. M., Kerse, N., Cardwell, C. R., Bradley, M. C., Ryan, C., & Hughes, C. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008165.pub4 · Cited by 511
The relationship between frailty and polypharmacy in older people: A systematic review
Gutiérrez‐Valencia, M., Izquierdo, M., Cesari, M., Casas‐Herrero, Á., Inzitari, M., & Martínez‐Velilla, N. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13590 · Cited by 480
Sarcopenia and Physical Frailty: Two Sides of the Same Coin
Cesari, M., Landi, F., Vellas, B., Bernabei, R., & Marzetti, E. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00192 · Cited by 468
Calderón-Larrañaga, A., Vetrano, D. L., Onder, G., Gimeno-Feliu, L. A., Coscollar-Santaliestra, C., Carfí, A., Pisciotta, M. S., Angleman, S., Melis, R. J. F., Santoni, G., et al. (2016) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glw233 · Cited by 425
Jokanovic, N., Tan, E. C. K., Dooley, M. J., Kirkpatrick, C. M., & Bell, J. S. (2015) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2015.03.003 · Cited by 415
Self-citationSalisbury, C., Man, M.-S., Bower, P., Guthrie, B., Chaplin, K., Gaunt, D. M., Brookes, S., Fitzpatrick, B., Gardner, C., Hollinghurst, S., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31308-4 · Cited by 414
Midão, L., Giardini, A., Menditto, E., Kardas, P., & Costa, E. (2018) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2018.06.018 · Cited by 397
Johnell, K., & Klarin, I. (2007) · Drug Safety · doi:10.2165/00002018-200730100-00009 · Cited by 386
Self-citationHospital admissions due to adverse drug reactions in the elderly. A meta-analysis
Oscanoa, T. J., Lizaraso, F., & Carvajal, A. (2017) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-017-2225-3 · Cited by 382
The epidemiology of polypharmacy in older adults: register-based prospective cohort study
Morin, L., Johnell, K., Laroche, M.-L., Fastbom, J., & Wastesson, J. W. (2018) · Clinical Epidemiology · doi:10.2147/clep.s153458 · Cited by 376
Self-citationAssociation between polypharmacy and death: A systematic review and meta-analysis
Leelakanok, N., Holcombe, A. L., Lund, B. C., Gu, X., & Schweizer, M. L. (2017) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2017.06.002 · Cited by 355 · cited 2×
“Some reviews have focused on the association between polypharmacy and a number of different health outcomes [17,18], whereas others have focused on polypharmacy and a specific health outcome (such as frailty [15] and mortality [16]).”
BackgroundCooper, J. A., Cadogan, C. A., Patterson, S. M., Kerse, N., Bradley, M. C., Ryan, C., & Hughes, C. M. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-009235 · Cited by 344
Dumbreck, S., Flynn, A., Nairn, M., Wilson, M., Treweek, S., Mercer, S. W., Alderson, P., Thompson, A., Payne, K., & Guthrie, B. (2015) · BMJ · doi:10.1136/bmj.h949 · Cited by 339
Increasing polypharmacy - an individual-based study of the Swedish population 2005-2008
Hovstadius, B., Hovstadius, K., Åstrand, B., & Petersson, G. (2010) · BMC Clinical Pharmacology · doi:10.1186/1472-6904-10-16 · Cited by 290
Moriarty, F., Hardy, C., Bennett, K., Smith, S. M., & Fahey, T. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-008656 · Cited by 266
Medication Non-Adherence Among Elderly Patients Newly Discharged and Receiving Polypharmacy
Pasina, L., Brucato, A. L., Falcone, C., Cucchi, E., Bresciani, A., Sottocorno, M., Taddei, G. C., Casati, M., Franchi, C., Djade, C. D., et al. (2014) · Drugs & Aging · doi:10.1007/s40266-014-0163-7 · Cited by 263
Relationship between polypharmacy and underprescribing
Kuijpers, M. A. J., Van Marum, R. J., Egberts, A. C. G., Jansen, P. A. F., & The OLDY (OLd people Drugs & dYsregulations) study group (2008) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2007.02961.x · Cited by 253
Pont, L., Alhawassi, T., Bajorek, B., & Krass, I. (2014) · Clinical Interventions in Aging · doi:10.2147/cia.s71178 · Cited by 245
Hanlon, J. T., & Schmader, K. E. (2013) · Drugs & Aging · doi:10.1007/s40266-013-0118-4 · Cited by 242
Lu, W.-H., Wen, Y.-W., Chen, L.-K., & Hsiao, F.-Y. (2015) · Canadian Medical Association Journal · doi:10.1503/cmaj.141219 · Cited by 240
Clinical assessment and management of multimorbidity: summary of NICE guidance
Farmer, C., Fenu, E., O’Flynn, N., & Guthrie, B. (2016) · BMJ · doi:10.1136/bmj.i4843 · Cited by 238
Johansson, T., Abuzahra, M. E., Keller, S., Mann, E., Faller, B., Sommerauer, C., Höck, J., Löffler, C., Köchling, A., Schuler, J., et al. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12959 · Cited by 234
Formica, D., Sultana, J., Cutroneo, P., Lucchesi, S., Angelica, R., Crisafulli, S., Ingrasciotta, Y., Salvo, F., Spina, E., & Trifirò, G. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1491547 · Cited by 211
Payne, R. A., Abel, G. A., Avery, A. J., Mercer, S. W., & Roland, M. O. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12292 · Cited by 204
Veronese, N., Stubbs, B., Noale, M., Solmi, M., Pilotto, A., Vaona, A., Demurtas, J., Mueller, C., Huntley, J., Crepaldi, G., et al. (2017) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2017.02.009 · Cited by 194
Haider, S. I., Johnell, K., Thorslund, M., & Fastbom, J. (2007) · Int. Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp45643 · Cited by 192
Self-citationElliott, L. S., Henderson, J. C., Neradilek, M. B., Moyer, N. A., Ashcraft, K. C., & Thirumaran, R. K. (2017) · PLOS ONE · doi:10.1371/journal.pone.0170905 · Cited by 161
Clinically important drug-disease interactions and their prevalence in older adults
Lindblad, C. I., Hanlon, J. T., Gross, C. R., Sloane, R. J., Pieper, C. F., Hajjar, E. R., Ruby, C. M., Schmader, K. E., & Panel, M. C. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.08.006 · Cited by 158
Brixner, D. I., Biltaji, E., Bress, A. P., Unni, S. K., Ye, X., Mamiya, T., Ashcraft, K. C., & BISKUPIAK, J. E. (2015) · Journal of Medical Economics · doi:10.3111/13696998.2015.1110160 · Cited by 151
Rawle, M. J., Cooper, R., Kuh, D., & Richards, M. (2018) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15317 · Cited by 145
Morin, L., Vetrano, D. L., Rizzuto, D., Calderón‐Larrañaga, A., Fastbom, J., & Johnell, K. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.02.028 · Cited by 137
Self-citationPark, H.-Y., Park, J.-W., Song, H. J., Sohn, H. S., & Kwon, J.-W. (2017) · PLOS ONE · doi:10.1371/journal.pone.0169463 · Cited by 136
Bonaga, B., Sánchez‐Jurado, P. M., Martínez-Reig, M., Ariza‐Zafra, G., Rodríguez‐Mañas, L., Gnjidic, D., Salvador, T., & Abizanda, P. (2017) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2017.07.008 · Cited by 136
Lalic, S., Sluggett, J. K., Ilomäki, J., Wimmer, B. C., Tan, E. C. K., Robson, L., Emery, T., & Bell, J. S. (2016) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2016.08.019 · Cited by 135
Self-citationClyne, B., Bradley, M. C., Hughes, C. M., Fahey, T. P., & Lapane, K. L. (2012) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2012.01.009 · Cited by 133
König, M., Spira, D., Demuth, I., Steinhagen-Thiessen, E., & Norman, K. (2018) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glx074 · Cited by 131
Polypharmacy: a necessary evil
Wise, J. (2013) · BMJ · doi:10.1136/bmj.f7033 · Cited by 123
Nishtala, P. S., & Salahudeen, M. S. (2015) · Gerontology · doi:10.1159/000368191 · Cited by 122
Wimmer, B. C., Bell, J. S., Fastbom, J., Wiese, M. D., & Johnell, K. (2016) · Annals of Pharmacotherapy · doi:10.1177/1060028015621071 · Cited by 119
Self-citationWang, R., Chen, L., Fan, L., Gao, D., Liang, Z., He, J., Gong, W., & Gao, L. (2015) · PLOS ONE · doi:10.1371/journal.pone.0142123 · Cited by 118
Polypharmacy in people with dementia: Associations with adverse health outcomes
Mueller, C., Molokhia, M., Perera, G., Veronese, N., Stubbs, B., Shetty, H., Codling, D., Huntley, J., & Stewart, R. (2018) · Experimental Gerontology · doi:10.1016/j.exger.2018.02.011 · Cited by 113
Pedrós, C., Formiga, F., Corbella, X., & Arnau, J. M. (2015) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-015-1974-0 · Cited by 112
Meta‐analysis of Interventions to Reduce Adverse Drug Reactions in Older Adults
Gray, S. L., Hart, L. A., Perera, S., Semla, T. P., Schmader, K. E., & Hanlon, J. T. (2017) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15195 · Cited by 108
Galvin, R., Moriarty, F., Cousins, G., Cahir, C., Motterlini, N., Bradley, M. C., Hughes, C. M., Bennett, K., Smith, S. M., Fahey, T. P., et al. (2014) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-014-1651-8 · Cited by 104
Dalton, K., O’Brien, G. L., O’Mahony, D., & Byrne, S. (2018) · Age and Ageing · doi:10.1093/ageing/afy086 · Cited by 104
Hanlon, P., Nicholl, B. I., Jani, B., McQueenie, R., Lee, D., Gallacher, K., & Mair, F. S. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-018404 · Cited by 100
Laflamme, L., Monárrez-Espino, J., Johnell, K., Elling, B., & Möller, J. (2015) · PLOS ONE · doi:10.1371/journal.pone.0123390 · Cited by 96
Self-citationSganga, F., Landi, F., Ruggiero, C., Corsonello, A., Vetrano, D. L., Lattanzio, F., Cherubini, A., Bernabei, R., & Onder, G. (2015) · Geriatrics & Gerontology International · doi:10.1111/ggi.12241 · Cited by 94
Montiel‐Luque, A., Núñez‐Montenegro, A. J., Aurioles, E. M., Canca‐Sánchez, J. C., Toro‐Toro, M. C., & Correa, J. A. G. (2017) · PLoS ONE · doi:10.1371/journal.pone.0171320 · Cited by 93
Schöttker, B., Saum, K.-U., Muhlack, D. C., Hoppe, L. K., Holleczek, B., & Brenner, H. (2017) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-017-2266-7 · Cited by 85
The composition of polypharmacy: A register-based study of Swedes aged 75 years and older
Wastesson, J. W., Cedazo-Mı́nguez, Á., Fastbom, J., Maioli, S., & Johnell, K. (2018) · PLoS ONE · doi:10.1371/journal.pone.0194892 · Cited by 81
Self-citationAdverse Geriatric Outcomes Secondary to Polypharmacy in a Mouse Model: The Influence of Aging
Huizer-Pajkos, A., Kane, A. E., Howlett, S. E., Mach, J., Mitchell, S. J., de Cabo, R., Le Couteur, D. G., & Hilmer, S. N. (2016) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glv046 · Cited by 75
Wastesson, J. W., Parker, M. G., Fastbom, J., Thorslund, M., & Johnell, K. (2011) · Age and Ageing · doi:10.1093/ageing/afr144 · Cited by 73
Self-citationVetrano, D. L., Villani, E. R., Grande, G., Giovannini, S., Cipriani, M. C., Manes-Gravina, E., Bernabei, R., & Onder, G. (2018) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2018.04.008 · Cited by 72
Optimizing elderly pharmacotherapy: polypharmacy vs. undertreatment. Are these two concepts related?
Blanco‐Reina, E., Ariza‐Zafra, G., Ocaña‐Riola, R., León, M., & Bellido-Estévez, I. (2014) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-014-1780-0 · Cited by 71
Polypharmacy and Gait Performance in Community–dwelling Older Adults
George, C. J., & Verghese, J. (2017) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14957 · Cited by 67
Franchi, C., Tettamanti, M., Pasina, L., Djignefa, C. D., Fortino, I., Bortolotti, A., Merlino, L., & Nobili, A. (2014) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-013-1621-6 · Cited by 61
Burt, J., Elmore, N., Campbell, S., Rodgers, S., Avery, A. J., & Payne, R. (2018) · BMC Medicine · doi:10.1186/s12916-018-1078-7 · Cited by 61
Niikawa, H., Okamura, T., Ito, K., Ura, C., Miyamae, F., Sakuma, N., Ijuin, M., Inagaki, H., Sugiyama, M., & Awata, S. (2017) · Geriatrics & Gerontology International · doi:10.1111/ggi.12862 · Cited by 59
Ryan-Atwood, T. E., Hutchinson-Kern, M., Ilomäki, J., Dooley, M. J., Poole, S. G., Kirkpatrick, C. M. J., Manias, E., Mitra, B., & Bell, J. S. (2017) · Drugs & Aging · doi:10.1007/s40266-017-0472-8 · Cited by 58
Wimmer, B. C., Dent, E., Visvanathan, R., Wiese, M. D., Johnell, K., Chapman, I. M., & Bell, J. S. (2014) · Drugs & Aging · doi:10.1007/s40266-014-0185-1 · Cited by 56
Self-citationDörks, M., Herget‐Rosenthal, S., Schmiemann, G., & Hoffmann, F. (2015) · Drugs & Aging · doi:10.1007/s40266-015-0333-2 · Cited by 55
Franchi, C., Marcucci, M., Mannucci, P. M., Tettamanti, M., Pasina, L., Fortino, I., Bortolotti, A., Merlino, L. G., & Nobili, A. (2015) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3938 · Cited by 50
Research Priorities for Optimizing Geriatric Pharmacotherapy: An International Consensus
Tan, E. C. K., Sluggett, J. K., Johnell, K., Onder, G., Elseviers, M. M., Morin, L., Vetrano, D. L., Wastesson, J. W., Fastbom, J., Taipale, H. T., et al. (2018) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2017.12.002 · Cited by 50
Self-citationSganga, F., Vetrano, D. L., Volpato, S., Cherubini, A., Ruggiero, C., Corsonello, A., Fabbietti, P., Lattanzio, F., Bernabei, R., & Onder, G. (2014) · The journal of nutrition health & aging · doi:10.1007/s12603-014-0029-z · Cited by 47
Polypharmacy Cut-Off for Gait and Cognitive Impairments
Langeard, A., Pothier, K., Morello, R., Lelong‐Boulouard, V., Lescure, P., Bocca, M., Marcelli, C., Descatoire, P., & Chavoix, C. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00296 · Cited by 47
Cognitive Decline and Polypharmacy in an Elderly Population
Oyarzún‐González, X., Taylor, K. C., Myers, S. R., Muldoon, S. B., & Baumgartner, R. (2015) · Journal of the American Geriatrics Society · doi:10.1111/jgs.13283 · Cited by 46
Chang, Y., Huang, S., Tao, P., & Chien, C. (2012) · BMC Nephrology · doi:10.1186/1471-2369-13-96 · Cited by 42
Craftman, Å. G., Johnell, K., Fastbom, J., Westerbotn, M., & Strauss, E. I. V. (2015) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2015.11.010 · Cited by 39
Self-citationLalic, S., Jamsen, K. M., Wimmer, B. C., Tan, E. C. K., Hilmer, S. N., Robson, L., Emery, T., & Bell, J. S. (2016) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-016-2075-4 · Cited by 39
Self-citationGuideline recommended treatments in complex patients with multimorbidity
Muth, C., & Glasziou, P. P. (2015) · BMJ · doi:10.1136/bmj.h5145 · Cited by 28 · cited 1×
“However, this increase is also driven by the use of single-disease guidelines that are not adapted for older adults with multimorbidity [33].”
BackgroundSutaria, A., Liu, L., & Ahmed, Z. (2016) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944716634579 · Cited by 28
Wastesson, J. W., Oksuzyan, A., Hjelmborg, J., & Christensen, K. (2016) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14416 · Cited by 17
Self-citationUpdated analysis on polypharmacy and mortality from the ESTHER study
Schöttker, B., Muhlack, D. C., Hoppe, L. K., Holleczek, B., & Brenner, H. (2018) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-018-2445-1 · Cited by 15
Expanding the Proportion of Life With Polypharmacy in Sweden: 2006–2013
Wastesson, J. W., Fastbom, J., & Johnell, K. (2016) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2016.07.006 · Cited by 11
Self-citationSirois, C., Tannenbaum, C., Gagnon, M.-È., Milhomme, D., & Émond, V. (2016) · Drugs & Therapy Perspectives · doi:10.1007/s40267-016-0299-0 · Cited by 9
The Polypharmacy Mouse Model: Novel Findings and New Opportunities
Johnell, K. (2016) · The Journals of Gerontology Series A · doi:10.1093/gerona/glw049 · Cited by 5
Self-citationDecade-long temporal trends in the utilization of preventive medicines by centenarians
Narayan, S. W., & Nishtala, P. S. (2016) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12487 · Cited by 5
Research works printed but not linked: 4
- O’Mahony D, 2015, Age Ageing, 44
- Duerden M, 2013, Polypharmacy and medicines optimisation: making it safe and sound
- Alhawassi TM, 2014, Clin Interv Aging, 9, 2079
- Calderón-Larrañaga A, 2016, J Gerontol Ser A Biomed Sci Med Sci, 72, 1417
Cited by
Polypharmacy in older adults: a narrative review of definitions, epidemiology and consequences
Pazan, F., & Wehling, M. (2021) · European Geriatric Medicine · doi:10.1007/s41999-021-00479-3 · Cited by 542
“Polypharmacy and specially psychotropics and anticholinergic drugs have been associated with cognitive impairment in various studies [62, 81].”
BackgroundInfluentialAn overview of prevalence, determinants and health outcomes of polypharmacy
Khezrian, M., McNeil, C. J., Murray, A. D., & Myint, P. K. (2020) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098620933741 · Cited by 443
Prevalence of multimorbidity and polypharmacy among adults and older adults: a systematic review
Nicholson, K., Liu, W., Fitzpatrick, D., Hardacre, K. A., Roberts, S., Salerno, J., Stranges, S., Fortin, M., & Mangin, D. (2024) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(24)00007-2 · Cited by 263
Polypharmacy, hospitalization, and mortality risk: a nationwide cohort study
Chang, T. I., Park, H., Kim, D. W., Jeon, E. K., Rhee, C. M., Kalantar-Zadeh, K., Kang, E. W., Kang, S.-W., & Han, S. H. (2020) · Scientific Reports · doi:10.1038/s41598-020-75888-8 · Cited by 263
Barriers and facilitators to deprescribing in primary care: a systematic review
Doherty, A. J., Boland, P., Reed, J., Clegg, A. J., Stephani, A.-M., Williams, N. H., Shaw, B., Hedgecoe, L., Hill, R., & Walker, L. (2020) · BJGP Open · doi:10.3399/bjgpopen20x101096 · Cited by 247
Metadata
- Authors
- Wastesson, J. W., Morin, L., Tan, E. C. K., & Johnell, K.
- Affiliations
- Stockholm University (SE)
- Corresponding author
- Wastesson, Jonas W.
- Venue
- Expert Opinion on Drug Safety
- Publisher
- Informa UK Limited
- Published
- 2018-12-02
- Volume
- 17
- Issue
- 12
- Pages
- 1185-1196
- ISSN
- 1474-0338 (ISSN-L)
- 1744-764X
- OpenAlex
- W2904281537
- Cited by
- 617
- References
- 96
- Citations by year
- 2026: 82 · 2025: 86 · 2024: 95 · 2023: 91 · 2022: 80 · 2021: 78 · 2020: 63 · 2019: 21
- FWCI
- 4.55
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Expert Opinion on Drug Safety (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Vetenskapsrådet (2015-03618)
- Topics
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Health Sciences › Medicine › Epidemiology › Chronic Disease Management Strategies
- Health Sciences › Health Professions › Pharmacy › Pharmacy and Medical Practices
- Keywords
- polypharmacy, older adults, multimorbidity, inappropriate prescribing, polypharmacy prevalence, adverse drug reactions, drug safety
- MeSH terms
- Age Factors, Aged, Pharmaceutical Preparations, Humans, Prevalence, Polypharmacy, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.